Summary & Overview
HCPCS J9228: Ipilimumab Injection, 1 mg
HCPCS Level II code J9228 denotes a 1 mg unit of ipilimumab administered as an injectable oncology therapy. Ipilimumab is an immune checkpoint inhibitor used in several cancer indications; reporting by milligram units enables granular billing for weight-based or protocol-specific dosing. Nationally, accurate use of J9228 affects drug cost accounting, prior authorization workflows, and facility revenue for outpatient infusion services.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise breakdown of how J9228 is used in claims, typical sites of service where administrations occur, and common modifiers and billing considerations affecting coverage and billing validation. The publication outlines standard benchmarks for unit reporting, contextual clinical indications for ipilimumab use, and relevant policy updates that influence payer coverage and prior authorization requirements.
This summary is intended for billing professionals, oncology practice administrators, and policy analysts seeking a national-level reference on coding and billing practices for ipilimumab unit reporting.
Billing Code Overview
HCPCS Level II code J9228 represents an injection of ipilimumab, 1 mg. This code is used to report administration of the drug formulation in settings where billing is reported by medication units rather than per infusion session.
Service type: Drug administration (intravenous immunotherapy agent)
Typical site of service: Hospital outpatient department, physician office, or infusion center
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with metastatic melanoma presents to the oncology infusion suite for treatment with ipilimumab. The medication is supplied and billed per milligram as J9228 (Injection, ipilimumab, 1 mg). The typical workflow begins with a pre-infusion nursing assessment including vital signs, allergy check, and verification of baseline liver function tests and thyroid function. The oncologist documents the indication, planned dose (weight-based or fixed per protocol), and consent. Pharmacy performs dose calculation, prepares the infusion using aseptic technique, and labels the product. Nursing initiates intravenous access, administers pre-medications if indicated, and starts the infusion under monitoring for immune-related adverse events. Post-infusion observation for infusion reactions and documentation of lot number, expiration, and amount administered are completed. Billing accounts for the drug using J9228 multiplied by the milligrams administered, with applicable modifiers to indicate circumstances such as administration by an outpatient hospital, deceased donor, or drug wastage reporting. Typical site of service is an outpatient hospital infusion center, oncology clinic, or physician office with infusion capability.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |